Chronic Myelogenous Leukemia: A Concise Update

By Hagop M. Kantarjian, Albert Deisseroth, Razelle Kurzrock, Zeev Estrov, and Moshe Talpaz

Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder of the primitive hematopoietic stem cell. It involves the myeloid, erythroid, megakaryocytic, B-, and sometimes T-lymphoid elements, but not the marrow fibroblasts. CML is characterized by a biphasic or triphasic course, and the presence of a chromosomal marker, the Philadelphia chromosome (Ph), in the leukemic cells. Proliferation is a shared feature of CML and other myeloproliferative disorders such as essential thrombocytosis, polycythemia vera, and myeloid metaplasia/myelofibrosis. Although these entities are usually distinct, overlap in presentation is occasionally observed, resulting in diagnostic confusion. Thus, it is important to confirm the diagnosis of CML by cytogenetic (Ph chromosome) or molecular studies, because the natural history and treatment of the myeloproliferative disorders are different.

Prognostic Factors and Models in CML

The disease heterogeneity led to analyses of the prognostic factors in CML (Table 1) and to the development of prognostic models that categorize patients into good-, intermediate-, or poor-risk groups with different survival expectations (median survival 2, 3 to 4, 5 to 6 years, respectively). A synthesis prognostic model, based on these studies, was proposed (Table 2).

CML Phases and Definitions

CML initially presents in an indolent or chronic phase course, easily controlled with therapy. With conventional treatment, it progresses into an accelerated phase that lasts for less than 1 to 1.5 years, and is followed by a blastic phase resulting in the patient’s death within 3 to 6 months. Twenty percent to 25% of patients die from complications of accelerated phase, while another 20% to 25% develop a blastic phase without the intermediate accelerated phase events. The definition of accelerated phase is vague. With more therapies reporting success in accelerated phase, a standardized definition, within which different approaches could be compared, is needed (Table 3).

Current Prognosis in CML

In the past, the prognosis of patients with CML was poor. The expected median survival was 3 years, and less than 20% of patients were alive 5 years after diagnosis. Prognosis has improved in recent cohorts of CML patients because of (1) earlier diagnosis, (2) improved anti-CML therapy, and (3) better supportive care. With routine screening tests, more patients are detected in the asymptomatic phase of CML, and with lesser degrees of tumor burden (Table 4). In contrast to the previous limited number of effective anti-CML agents (hydroxyurea or busulfan), several additional active drugs and combinations are now available that may improve patient prognosis. These include interferons, low-dose cytosine arabinoside (ara-C), intensive chemotherapy, and autologous bone marrow transplantation (BMT). Presently, the median survival in CML is about 60 to 65 months. The survival rates are 75% to 85% at 3 years, and 50% to 60% at 5 years (Fig 1). With α interferon (IFN-α) regimens, 20% to 25% of all patients remain alive with major durable cytogenetic responses on therapy, as discussed later.

Philadelphia Chromosome, Molecular Abnormalities, and Disease Pathophysiology

The Ph chromosome initially described a shorter long arm of chromosome 22. It is the result of breaks on chromosomes 9 and 22, with a reciprocal translocation of the distal genetic material, t(9;22)(q34;q11). This translocation encodes for a 210-kD fusion protein. The latter, presumably through its increased tyrosine kinase activity, changes normal hematopoietic cells into CML cells.

In Ph-positive CML, the breakpoints within BCR have been assigned to 3’ or 5’ locations. Depending on whether the joining is between exon 3 or exon 2 of the BCR and exon 2 of ABL, two different RNA messages are formed: b3a2 and b2a2. While the 3’ breakpoints often result in b3a2 and 5’ breakpoints in b2a2 messages, some patients with 5’ breakpoints (zone 3) produce the b3a2 message. These abnormalities at the DNA and RNA levels have been associated with different prognostic implications, but the findings remain controversial.

In Ph-positive acute leukemia, 50% to 80% of patients have a breakpoint proximal to the BCR region, which results in a smaller 7.5-kb RNA and 190-kD (p190) message. These changes have been associated with lymphoid lineage-specific involvement (in contrast to multilineage involvement with p210 disease), and with shorter periods to acute transformation in animal models. However, except for the development of second chronic phase disease in p210 Ph-positive acute leukemia, the clinical features and prognoses are similar in p210 versus p190 acute leukemias.

From the Sections of Leukemia and Biological Studies, the Division of Medicine, M.D. Anderson Cancer Center, Houston, TX. Submitted February 5, 1993; accepted April 30, 1993.
H.M.K. is a Scholar of the Leukemia Society of America.
Address reprint requests to Hagop M. Kantarjian, MD, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 61, Houston, TX 77030.
© 1993 by The American Society of Hematology.
0006-4971/93/8203-0043/00/0

Blood, Vol 82, No 3 (August 1), 1993: pp 691-703
The mechanisms underlying the growth advantage of CML over normal hematopoietic cells are unknown. The Ph-associated molecular abnormalities reduce the adherence of CML cells to the stromal matrix, thus decreasing the time of stroma: hematopoietic cell interaction. This abrogates the normal maturation of cell surface signals (cytoadhesion molecules, HLA-DR) required for the normal differentiation of late progenitor cells, or induction of apoptosis, may be helpful and should be investigated.

RATIONAL FOR INVESTIGATIONAL TREATMENTS IN CML

In the 1970s, intensive chemotherapy was developed, as for acute leukemia, to attempt elimination of the Ph-positive CML clones. The degree of Ph suppression, or cytogenetic response, was intense but brief. It was also argued that while the bone marrow of patients with CML is overwhelmed by the growth advantage of the Ph-positive CML cells, a suppressed normal stem cell pool persisted, which could be exploited therapeutically. Treatments that reversed the growth advantage in favor of normal over Ph-positive cells would hopefully change the course of CML, and improve patient prognosis.

Preclinical models have established the causal association between the Ph-associated molecular events and the initiation and perpetuation of CML disease. In such a model, cDNA encoding p210BCR-ABL was introduced into mouse marrow cells, which were reinfused into lethally irradiated mice. After 2 to 8 weeks, some of the mice developed CML-like disorders, including (1) leukocytosis and splenomegaly, (2) monocytosis and macrophage extramedullary tu-
CHRONIC MYELOGENOUS LEUKEMIA

Table 4. Changing Presentation of Patients With Ph-Positive Chronic Phase CML by Year of Referral

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Category</th>
<th>Before 1983 (N = 326)</th>
<th>Since 1983 (N = 494)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>≥60</td>
<td>18</td>
<td>12</td>
<td>.03</td>
</tr>
<tr>
<td>Asymptomatic diagnosis</td>
<td>Yes</td>
<td>15</td>
<td>37</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Hematomegaly</td>
<td>Yes</td>
<td>46</td>
<td>18</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>Yes</td>
<td>76</td>
<td>54</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>&lt;12</td>
<td>58</td>
<td>48</td>
<td>.01</td>
</tr>
<tr>
<td>WBC count (&gt;10^9/L)</td>
<td>≥100</td>
<td>69</td>
<td>56</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Platelet count (10^9/L)</td>
<td>≥700</td>
<td>28</td>
<td>19</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Peripheral blasts</td>
<td>Yes</td>
<td>65</td>
<td>56</td>
<td>.03</td>
</tr>
<tr>
<td>Peripheral basophils (%)</td>
<td>≥7</td>
<td>17</td>
<td>14</td>
<td>NS</td>
</tr>
<tr>
<td>Marrow blasts (%)</td>
<td>≥5</td>
<td>16</td>
<td>9</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Marrow basophils (%)</td>
<td>≥3</td>
<td>40</td>
<td>35</td>
<td>NS</td>
</tr>
<tr>
<td>Additional chromosomal abnormalities other than Ph within 4 wks from diagnosis</td>
<td>Yes</td>
<td>7</td>
<td>6</td>
<td>NS</td>
</tr>
</tbody>
</table>

Abbreviation: NS, not significant.

has been observed occasionally when unpredictable prolonged myelosuppression is induced by busulfan therapy. With hydroxyurea therapy, the cytogenetic responses are minor and transient. While these treatments offer effective disease control and survival prolongation, they have not altered the inexorable transformation of CML into the terminal phases.

**IFN-α**

Therapy with the partially pure human leukocyte IFN, in patients with chronic phase CML, demonstrated a complete hematologic response (CHR) rate of 70%, and a cytogenetic response rate of 40%. This was followed by several trials with the recombinant α interferons (IFN-α) alone, or in combinations with other biologic agents (IFN-γ, DFMO), with initial or later cyclic intensive chemotherapy, hydroxyurea, and low-dose ara-C. These studies have confirmed that CHRs are achieved in 70% to 80% of patients, cytogenetic responses in 40% to 60%, and major cytogenetic responses (Ph suppression to <35%) in 30% to 40% (Table 5). Cytogenetic responses were categorized as complete if Ph-positive cells were 0%, partial if they were 1% to 34%, and minor if they were 35% to 90%. The median survival of patients treated with IFN-α regimens in early chronic phase CML is shown in Fig 1.

Results of IFN-α therapy in CML have now been reported by several investigators (Table 6). Differences in CHR and cytogenetic response rates in various trials may be related to (1) the CML phase in which patients are treated, (2) the patient risk group and pretreatment characteristics, and (3) the dose-schedule of IFN-α (Table 7). Alimena et al. randomized patients to receive IFN-α 2 × 10^6 U/m² three times weekly, or 5 × 10^6 U/m² three times weekly. Among 33 patients treated at the lower dose schedule, 8 (24%) achieved CHR, compared with 14 of 30 patients (47%) treated at the higher dose schedule (P = .06). Among 21 patients who failed to achieve a response at the lower dose schedule and who were treated at the higher dose schedule, 8 (38%) achieved CHR. On the daily dose schedule that they used subsequently, 7 of the first 8 patients treated

Fig 1. Survival of patients with Ph-positive CML treated with IFN-α-based regimens in early chronic phase.

THERAPY OF CML

**Conventional Therapy**

Until 1980, hydroxyurea and busulfan were the two most effective anti-CML agents. They were superior to irradiation or other drugs such as melphalan, 6 mercaptopurine, and chlorambucil, provided excellent disease control with minimal toxicity, were inexpensive, and were administered orally. Busulfan provided longer periods of disease control, but was associated with unpredictable prolonged myelosuppression (10% or less of patients); organ fibrosis (lungs, heart, marrow); and Addison's-like disease. It is still frequently used in countries where socioeconomic considerations prevail, and in older patients who are not candidates for BMT, and who do not want frequent follow-ups. Hydroxyurea has been the drug of choice in patients who are candidates for BMT because of its better toxicity profile. It is used in intermittent schedules to keep the white blood cell (WBC) count between 10 and 50 × 10^9/L, or in continuous exposure schedules to control the WBC count at a range of 2 to 5 × 10^9/L, ie, a minimal CML tumor burden.

Busulfan provided longer periods of disease control, but was associated with unpredictable prolonged myelosuppression (10% or less of patients); organ fibrosis (lungs, heart, marrow); and Addison's-like disease. It is still frequently used in countries where socioeconomic considerations prevail, and in older patients who are not candidates for BMT, and who do not want frequent follow-ups. Hydroxyurea has been the drug of choice in patients who are candidates for BMT because of its better toxicity profile. It is used in intermittent schedules to keep the white blood cell (WBC) count between 10 and 50 × 10^9/L, or in continuous exposure schedules to control the WBC count at a range of 2 to 5 × 10^9/L, ie, a minimal CML tumor burden.

Both agents produce hematologic remissions in 70% to 80% of patients with chronic phase CML. However, these are "pseudoremissions" because cytogenetic studies in treated patients show persistence of Ph-positive cells in the majority (>90%) of marrow metaphases. Ph suppression
achieved CHR (87%). In early chronic phase CML, IFN-α at $5 \times 10^6$ U/m² daily, or at the lower maximally tolerated individual dose, is associated with better hematologic and cytogenetic response rates.

Side effects. IFN-α is associated with early flulike side effects (fever, chills, postnasal drip, anorexia, lack of appetite) in most patients, which (1) are not dose-limiting, (2) can be managed symptomatically (bedtime dose, acetaminophen), and (3) are minimized by starting IFN-α at 50% of the dose for the first week. Reducing the initial WBC counts to 10 to 20 $\times 10^3$/µL with chemotherapy also reduces the leukocytosis-associated side effects (fever, chills, musculoskeletal pains). Tachyphylaxis develops within 1 to 2 weeks. Late side effects are dose-limiting in 10% to 25% of patients, and include persistent fatigue; weight loss; neurotoxicity (depression); a triad of depression, fatigue, and insomnia (manageable with small doses of antidepressants at bedtime); and occasional immune-mediated complications. These have included immune-mediated hemolysis or thrombocytopenia, collagen vascular disorders such as rheumatoid arthritis and systemic lupus erythematosus, and immune-mediated nephrotic syndrome and hypothyroidism. Rare cases of cardiac dysfunction (arrhythmias, congestive heart failure) have been reported and may be immune-mediated. These necessitate immediate discontinuation of IFN-α, standard treatment for heart failure, and steroid ther-

Table 5. Results of IFN-α Studies in CML at MDACC

<table>
<thead>
<tr>
<th>Study-Year (reference)</th>
<th>No. Patients</th>
<th>CHR</th>
<th>Any</th>
<th>Major</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human IFN-α–1982 (40)</td>
<td>51</td>
<td>71</td>
<td>41</td>
<td>18</td>
</tr>
<tr>
<td>Recombinant IFN-α–1984 (41)</td>
<td>35</td>
<td>80</td>
<td>54</td>
<td>40</td>
</tr>
<tr>
<td>IFN-α + IFN-γ–1985</td>
<td>36</td>
<td>68</td>
<td>47</td>
<td>31</td>
</tr>
<tr>
<td>IFN-α + cyclic intensive chemotherapy–1986</td>
<td>68</td>
<td>82</td>
<td>66</td>
<td>43</td>
</tr>
<tr>
<td>IFN-α + hydrea–1988</td>
<td>79</td>
<td>86</td>
<td>62</td>
<td>41</td>
</tr>
<tr>
<td>IFN-α + low-dose ara-C–1989</td>
<td>44</td>
<td>70</td>
<td>55</td>
<td>32</td>
</tr>
<tr>
<td>Total</td>
<td>313</td>
<td>77</td>
<td>56</td>
<td>35</td>
</tr>
</tbody>
</table>

Table 6. Results of IFN-α Studies in CML

<table>
<thead>
<tr>
<th>Study (reference)</th>
<th>No. Patients</th>
<th>CHR</th>
<th>Ph Suppression</th>
</tr>
</thead>
<tbody>
<tr>
<td>M.D. Anderson Cancer Center</td>
<td>313</td>
<td>240 (77)</td>
<td>175 (56)</td>
</tr>
<tr>
<td>Alimena et al (42)</td>
<td>63</td>
<td>29 (46)</td>
<td>27 (43)</td>
</tr>
<tr>
<td>Niederle et al (43)</td>
<td>41</td>
<td>23 (56)</td>
<td>14 (34)</td>
</tr>
<tr>
<td>Ozer et al (44)</td>
<td>107</td>
<td>63 (59)</td>
<td>31/80 (44)</td>
</tr>
<tr>
<td>Freund et al (45)</td>
<td>27</td>
<td>10 (37)</td>
<td>5 (19)</td>
</tr>
<tr>
<td>Montastruc et al (46)</td>
<td>38</td>
<td>32 (84)</td>
<td>24 (63)</td>
</tr>
</tbody>
</table>
apy if indicated. Immune-mediated hypothyroidism does not require IFN-α discontinuation and is managed by replacement therapy.

Dose reductions are required for (1) grade 3 or 4 toxicity (hold therapy until recovery then start at 50%), (2) persistent grade 2 toxicity not improved with symptomatic support (25% dose reduction), or (3) if the WBC count decreases to below 2 × 10^9/L or platelets below 60 × 10^9/L (25% dose reductions). Elderly patients (age 60 years or older) tolerate therapy less well than younger patients.

**Long-term follow-up of cytogenetic responses.** To evaluate the long-term course of patients, and allow for maturation and follow-up of cytogenetic responses, patients treated until 1988 were reviewed. Cytogenetic studies were performed every 3 months in the first 2 years, then every 4 to 6 months. The duration of cytogenetic response is calculated from the time of the achievement of any cytogenetic response (Fig 3, A and B), or from the time of achievement of the best cytogenetic response (Fig 3, C), until recurrence of more than 90% Ph-positive cells. Durable cytogenetic responses were noted in about 30% of patients (Table 8, Fig 3).

Of the 49 patients achieving complete cytogenetic remission (CR), 45 (92%) have durable cytogenetic responses for periods ranging between 2 and 8 years, whereas 4 have lost their cytogenetic response (ie, reverted back to 90% or more Ph-positive metaphases) (Table 8). Thirty-four of the 49 patients were in a continuous cytogenetic CR (ie, Ph status 0%) with repeated studies. Sixteen of the 34 patients were taken off IFN-α because of toxicities (5 patients) or patient or physician choice (11 patients); continuous cytogenetic CR for more than 2 years; 7 of the 16 continue in cytogenetic CR for 12+ to 56+ months (median 34 months); 6 had Ph recurrence but went back to 0% Ph-positivity (3 patients) or less than 35% Ph-positive (3 patients) with reinstitution of IFN-α; and 3 had recurrence of Ph-positive metaphases but are on observation off IFN-α therapy (cytogenetic but not hematologic relapse). Among the remaining 11 patients, 6 fluctuate with Ph-positive metaphases of 0% to 10%, whereas 5 have more than 10% Ph-positive metaphases, but are in continuous cytogenetic response on IFN-α therapy (2 with less than 35% Ph-positive metaphases). Thus, currently 28 (18 + 7 + 3) of the 49 patients (57%) are in continuous cytogenetic CR on or off IFN-α therapy; while 39 patients (28 cytogenetic CR, 11 cytogenetic PR) (80% of total) are in a durable major cytogenetic response.

**Associations of cytogenetic responses with prognosis.** Accounting for the time to achieve the best cytogenetic response (median time 22 months for complete, 18 months for partial, 12 months for minor cytogenetic responses, respectively), the duration of cytogenetic response was longest in patients achieving a complete cytogenetic response (Fig 3). This is not surprising because, in most other tumors, the lowest detectable tumor burden achieved (ie, CR) is the only response that is associated with durable remissions and with prolongation of survival or disease-free survival. Once such a low tumor burden is obtained in a substantial fraction of patients (40% to 60%), significant survival prolongation may be observed for the total population under treatment. A similar significant association between the cytogenetic response at 12 months and survival was also reported by the Italian Cooperative Study Group in CML.48 Using a landmark analysis, Ozer et al did not find a significant correlation between cytogenetic response and remission duration or survival. However, their analysis combined cytogenetic CR and PR as one category (which might have diluted the association), and only 14 patients were in cytogenetic CR.44

Zuffa et al13 updated their comparative study that randomized patients to IFN-α at 5 × 10^6 U/m² daily (218 patients) or hydroxyurea (104 patients). The long-term follow-up showed major cytogenetic response at 4 years in 25% of patients receiving IFN-α and in 0% of those treated with hydroxyurea. The median survivals were significantly better in IFN-α-treated patients overall (not reached vs 49 months, P = .004), and within low-intermediate (not reached vs 50 months, P = .04), and high-risk groups (56 vs 38 months, P = .02).51

Investigating the long-term prognosis of patients, Lazzarino et al12 analyzed IFN-α as a treatment variable for prognosis, showing it to be significantly favorable in good- and intermediate-risk patients, but not in those with poor-risk disease.

**Interpretation of the maturing experience.** While the results of Zuffa12 and Lazzarino et al12 support association between IFN-α and improved survival, the fact that only 25% of patients have complete responses suggests that the beneficial effect on survival in the total denominator may not be reproducible in other studies. In general, to observe the effect in the whole population, at least 40% of patients should achieve a minimal tumor burden (ie, CR for solid tumors, cytogenetic CR for CML) if that response is associated with at least a 25% improvement in prognosis (10% overall improvement; P = .05; power 80%; 100 patients in study and control groups).

These findings have important therapeutic implications. If the positive effect of IFN-α on survival of the total population is shown in other studies, the treatment recommendations might change to advise continuing IFN-α therapy in all patients with CML, regardless of the cytogenetic response, aiming for the survival benefit. However, if the survival association is not solidly confirmed, then only patients...
who achieve a major cytogenetic response would continue on IFN-α therapy (discussed later under “Proposed Sequence of Treatments in CML”). Future studies with IFN-α combinations would then aim to achieve complete cytogenetic response rates of 40% or more before other randomized clinical trials are planned.

In summary, the maturing experience with IFN-α regimens (1) shows median survivals of 60 to 65 months with 25% of patients being in durable cytogenetic remissions, and (2) suggests the superiority of IFN-α over conventional therapy, as measured by cytogenetic response and survival.

Other IFNs

The promising results with IFN-α encouraged the search for other IFNs or biologic agents with potential anti-CML activity. IFN-γ differs from α and β IFNs in its biologic properties, mechanisms of action, and cell surface receptors. Studies investigating γ-IFN in CML have shown definite but modest activity, with a CHR rate range of 20% to 30%. Combining IFN-α with γ-IFN in (1) a simultaneous dose schedule using the full dose of IFN-α and a low (in vitro synergistic) dose of IFN-γ, or (2) in a sequential fashion using alternate-day or alternate-week schedules of the two IFNs, has produced disappointing results. IFN-β has had limited investigation in CML with negative results. Studies with the “concensus” IFN, a synthetized molecule that presumably incorporates the active moieties of different subspecies of α IFNs, are underway.

Combinations of IFN-α and Other Agents

To improve the prognosis beyond that obtained with IFN-α alone, investigations have combined it with other
effective anti-CML agents including busulfan, hydroxyurea, initial or cyclic intensive chemotherapy, and low-dose araC. Combining busulfan with IFN-α proved to be difficult because of the cumulative effect on prolonged myelosuppression. Adding intensive chemotherapy to IFN-α was not associated with better results than with IFN-α alone, perhaps because of the short-term exposure of CML cells to the effect of chemotherapy (only 3 initial courses, or once every 6 months) mandated by the serious myelosuppressive side effects.57

The combination of IFN-α and hydroxyurea is attractive in clinical practice because of its ease of administration. This regimen provides (1) rapid disease control, (2) a better CHR rate, (3) a lower incidence of side effects attributed to leukocytosis (fever, chills, musculoskeletal syndrome), and (4) a longer duration of disease control. However, it is not associated with improved cytogenetic response rates (overall, major, durable).

Ara-C was combined with IFN-α because of its selective anti-CML effect in vitro, and its capacity to induce cytogenetic remissions in treated patients.58,59 With low-dose ara-C therapy in chronic phase CML, Sokal and Bigner58 and Cannistra et al59 observed cumulatively Ph suppression down to a median of 27% Ph-positive metaphases (range 0% to 84%) in 6 of 8 patients. Low-dose ara-C is associated with less myelosuppressive side effects than intensive chemotherapy, and provides longer exposure of CML cells to the treatment (about 1 week every month) and, hence, potentially better suppression of CML clonal evolution. In late chronic-phase CML, the combination of IFN-α and low-dose ara-C was associated with significantly higher CHR rates compared with IFN-α alone, a trend for better cytogenetic response rates, and with significantly longer survival60 (Table 9). It also induced suppression of clonal evolution in 5 of 20 patients (25%) treated in accelerated phase (16 patients with clonal evolution only, see Table 11; 4 patients with other accelerated phase features with or without clonal evolution).

In a randomized study, Guilhot et al61 treated patients with early chronic-phase CML with IFN-α plus low-dose ara-C (39 patients) or with IFN-α alone (36 patients). Both groups had received hydroxyurea during remission induction to achieve rapid cytoreduction until CHR was obtained. Compared with IFN-α therapy alone, the combination of IFN-α plus low-dose ara-C was associated with a higher complete cytogenetic response rate (8% v 28%; P < .01) and with nonsignificant trends for a higher major cytogenetic response rate (30% v 44%), and for disease control at 12 months (60% v 80%).

### Allogeneic BMT

Allogeneic BMT is curative in CML, with significantly better disease-free survival rates in chronic, compared with accelerated or blastic phases (Table 10). Candidate patients should be offered matched or one antigen-mismatched related allogeneic BMT in chronic phase, before disease transformation.

The timing of allogeneic BMT in chronic phase is more controversial because of the risks of the procedure. In chronic phase CML, better results are achieved (1) in younger patients, (lower risk of early and graft-versus-host disease (GVHD)-associated mortality), (2) when BMT is performed in early chronic phase, and (3) in patients not exposed to busulfan therapy.62-64 A lower incidence of BMT morbidity and mortality from GVHD has been observed with T-cell-depleted BMT, which was counterbalanced by the higher incidence of graft failure and leukemia relapse.66,67

The lower disease-free survival rates with transplantation later in chronic phase CML are not due to a higher incidence of leukemia relapse (ie, more resistant clones from longer disease duration), but to a higher BMT mortality. This suggests that host- (age, organ function) or treatment-related factors (prior busulfan exposure) are partly responsible for this difference. This difference in survival rates, while statistically significant in the international BMT registry (IBMTR) in over 1,000 patients evaluated, is in the range of 5% to 10%, and may not be relevant to individual patients,64 particularly when accounting for age and prior therapy considerations. In a subset analysis of patients receiving non-T-cell–depleted allogeneic BMT, Goldman et al69 reported both the duration of chronic phase, and exposure to busulfan therapy, to be independent prognostic factors for patient outcome. The European BMT Registry (EBMTR) has not shown a survival difference by time to BMT, but patients

<table>
<thead>
<tr>
<th>CML Phase</th>
<th>Disease-free Survival</th>
<th>Leukemia Relapse</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Results by CML Phase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic</td>
<td>40-60</td>
<td>5-30</td>
</tr>
<tr>
<td>Accelerated</td>
<td>15-25</td>
<td>50-60</td>
</tr>
<tr>
<td>Blastic</td>
<td>15 or less</td>
<td>60-80</td>
</tr>
<tr>
<td>B. Results by Age in Chronic-Phase CML</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early mortality</td>
<td>5-10</td>
<td>10-20</td>
</tr>
<tr>
<td>Late mortality</td>
<td>5-10</td>
<td>10-20</td>
</tr>
<tr>
<td>Leukemia relapse</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Disease-free survival</td>
<td>60-70</td>
<td>40-50</td>
</tr>
</tbody>
</table>

Parameter | % With Parameter by Age of Patients (yrs) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;20</td>
<td>20-29</td>
</tr>
<tr>
<td>≥30</td>
<td>30-40</td>
</tr>
</tbody>
</table>

Table 9. Therapy With IFN-α Alone or With Low-Dose ara-C in Late Chronic-Phase CML

<table>
<thead>
<tr>
<th>CML Phase</th>
<th>Therapy</th>
<th>No. (%)</th>
<th>CHR</th>
<th>Cytogenetic Response</th>
<th>3-yr Survival (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Late chronic</td>
<td>IFN-α + ara-C</td>
<td>40 (22)</td>
<td>16 (15)</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IFN-α</td>
<td>39 (11)</td>
<td>2 (6)</td>
<td>48</td>
<td>P = .02</td>
</tr>
<tr>
<td>Accelerated (clonal evolution only)</td>
<td>IFN-α + ara-C</td>
<td>16 (8)</td>
<td>4 (25)</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IFN-α</td>
<td>9 (6)</td>
<td>2 (22)</td>
<td>49</td>
<td></td>
</tr>
</tbody>
</table>
with worse expected prognosis may have received transplants earlier in chronic-phase CML. The long-term follow-up studies from both registries show disease-free survival rates of 38% at 5 years, a figure lower than projections from earlier reports, with a continuous pattern of late relapses (relapse rates 10% at 2 years, 25% at 5 years). This late relapse pattern, not seen in acute leukemia, may be caused by the more primitive stem cell involvement in CML. Both of these updates have included patients who had undergone T-cell-depleted allogeneic BMT, and the disease-free survival rates in non-T-cell-depleted BMT are higher. In the EBMTR studies, patients with prior IFN exposure and those who underwent splenectomy before BMT did not have different outcomes compared with those who had not. 70

Allogeneic BMT with matched unrelated donors (MUD) has yielded encouraging results. 48,71 The median time from the start of the search to BMT was 8.4 months. The procedure was associated with (1) a higher incidence of graft failure (16%), and (2) higher incidences of grade III and IV acute GVHD (54%) and of extensive chronic GVHD (52%). Overall, the 2-year disease-free survival rate was 31%, and ranged from 14% to 43% depending on the patient age and degree of HLA-matching.71 Thus, while promising, MUD allogeneic BMT is presently associated with significant morbidity and mortality, particularly in older patients. It is indicated in patients with a poor prognosis (acute leukemia in first relapse, CML transformation). Its benefit versus risk should be carefully weighed in chronic-phase CML, particularly among older patients, in relation to other investigational modalities, and to the natural course of the disease with current treatments.

**Proposed Sequence of Treatments in CML**

All patients with CML transformed (accelerated, blastic) phases and those with a syngeneic donor should be offered allogeneic BMT if they are candidates for the procedure (age less than 50 to 55 years, available matched or one antigen mismatched related donor).

Younger patients (age cut-off defined by investigators according to their experience in different age subgroups) would be offered related allogeneic BMT in early chronic phase when possible, because of the high disease-free survival rates and low morbidity and mortality in these age groups.

For the remaining patients, an initial trial of IFN-α-containing regimen may be indicated. If patients achieve a significant response (any cytogenetic response at 6 months, Ph-positive cells less than 50% to 65% at 12 months) they will continue on therapy unless the response is lost. The others will be offered allogeneic BMT from related donors, or investigational treatments such as MUD allogeneic BMT, autologous BMT, or new agents (homoharringtonine, others) or combinations (Fig 4).

Patients who achieve a complete durable cytogenetic response documented over a 6-month period should have an autologous marrow storage. In them, IFN-α therapy should be held for at least 1 month before autologous marrow preservation for ease of procedure and storage of an adequate marrow for BMT (3 x 10^6 nucleated cells or more/kg, 10^8 or more GMFSC/kg).

IFN-α therapy was thought not to benefit patients in late chronic-phase CML. Recent studies showing a survival advantage of IFN-α versus hydroxyurea 51,52 and of IFN-α plus low-dose ara-C in late chronic phase CML 48 suggest otherwise. Patients in late chronic-phase CML who are not candidates for allogeneic BMT (related, MUD), should consider an investigational trial before deciding on maintenance with IFN-α therapy (IFN-α plus low-dose ara-C or hydroxyurea) for optimal benefit (Fig 4).

**Autologous BMT**

Autologous BMT in CML transformed phases was associated with a high rate of reestablishment of a short-lasting second chronic phase. In chronic-phase CML, autologous BMT with infusions of predominantly Ph-positive autologous stem cells (peripheral, marrow) produced transient cytogenetic remissions. 72,73 Follow-up studies have suggested a longer survival with autologous BMT. However, similar to autologous BMT studies in other tumors (acute leukemia in first CR, multiple myeloma, breast and lung cancers), it is difficult to dissociate the effect of patient selection, and lead time bias, from that of BMT. Comparative studies with patients treated with other modalities and matched for age, organ function, and time to BMT may help clarify the issue.

Autologous stem cell transplant using in vivo (chemotherapy, IFN) or in vitro purging (chemotherapy, IFNs, long-term liquid cultures, positive selection for CD34-positive normal stem cells, negative selection for CML cells) 74,75 is an exciting strategy. The purpose is to infuse stem cells maximally enriched with normal hematopoietic cells and depleted of Ph-positive clones.

Using long-term liquid (Dexter) cultures for in vitro purging of CML marrows, Barnett et al. 76 screened 88 patients and identified 33 (38%) to be suitable for the large-scale purging procedure. Twenty of the 33 patients underwent purged autologous BMT (14 in first chronic phase; 6 in later phases and those with a syngeneic donor should be offered allogeneic BMT if they are candidates for the procedure (age less than 50 to 55 years, available matched or one antigen mismatched related donor).

Younger patients (age cut-off defined by investigators according to their experience in different age subgroups) would be offered related allogeneic BMT in early chronic phase when possible, because of the high disease-free survival rates and low morbidity and mortality in these age groups.

For the remaining patients, an initial trial of IFN-α-containing regimen may be indicated. If patients achieve a significant response (any cytogenetic response at 6 months, Ph-positive cells less than 50% to 65% at 12 months) they will continue on therapy unless the response is lost. The others will be offered allogeneic BMT from related donors, or investigational treatments such as MUD allogeneic BMT, autologous BMT, or new agents (homoharringtonine, others) or combinations (Fig 4).

Patients who achieve a complete durable cytogenetic response documented over a 6-month period should have an autologous marrow storage. In them, IFN-α therapy should be held for at least 1 month before autologous marrow preservation for ease of procedure and storage of an adequate marrow for BMT (3 x 10^6 nucleated cells or more/kg, 10^8 or more GMFSC/kg).

IFN-α therapy was thought not to benefit patients in late chronic-phase CML. Recent studies showing a survival advantage of IFN-α versus hydroxyurea 51,52 and of IFN-α plus low-dose ara-C in late chronic phase CML 48 suggest otherwise. Patients in late chronic-phase CML who are not candidates for allogeneic BMT (related, MUD), should consider an investigational trial before deciding on maintenance with IFN-α therapy (IFN-α plus low-dose ara-C or hydroxyurea) for optimal benefit (Fig 4).

**Autologous BMT**

Autologous BMT in CML transformed phases was associated with a high rate of reestablishment of a short-lasting second chronic phase. In chronic-phase CML, autologous BMT with infusions of predominantly Ph-positive autologous stem cells (peripheral, marrow) produced transient cytogenetic remissions. 72,73 Follow-up studies have suggested a longer survival with autologous BMT. However, similar to autologous BMT studies in other tumors (acute leukemia in first CR, multiple myeloma, breast and lung cancers), it is difficult to dissociate the effect of patient selection, and lead time bias, from that of BMT. Comparative studies with patients treated with other modalities and matched for age, organ function, and time to BMT may help clarify the issue.

Autologous stem cell transplant using in vivo (chemotherapy, IFN) or in vitro purging (chemotherapy, IFNs, long-term liquid cultures, positive selection for CD34-positive normal stem cells, negative selection for CML cells) 74,75 is an exciting strategy. The purpose is to infuse stem cells maximally enriched with normal hematopoietic cells and depleted of Ph-positive clones.

Using long-term liquid (Dexter) cultures for in vitro purging of CML marrows, Barnett et al. 76 screened 88 patients and identified 33 (38%) to be suitable for the large-scale purging procedure. Twenty of the 33 patients underwent purged autologous BMT (14 in first chronic phase; 6 in later
phases). Graft failure was noted in 5 patients (20%). Of 14 evaluable patients by cytogenetic studies, 12 (86%; 60% of total) achieved a cytogenetic CR, and the other 2 had a cytogenetic PR. After a median follow-up of 15 months (range 6 to 51 months), Ph-positive recurrence was observed in 8 of the 12 patients, and 6 received IFN-α therapy. Five patients (20% of total) are currently disease free for 14, 28, 29, 32, and 51 months, the latter 2 with IFN-α therapy.²⁴

Alimena²⁵ summarized the Italian experience in patients with CML who underwent autologous BMT intensification if they had not achieved a desirable cytogenetic response with IFN-α therapy. Fifteen patients, whose median percent of Ph-positive cells was 72% after a median duration of 20 months of IFN-α therapy, had marrow harvest and underwent autologous BMT: 5 remain in cytogenetic remission (Ph-positive less than 35% in 2, and more than 35% in 3).³⁵ In that same analysis, of a total of 48 patients undergoing autologous BMT before (26 patients) or after IFN-α therapy (22 patients), 11 (23%) achieved favorable cytogenetic responses.³⁵

These relatively mature studies, as well as others using different forms of in vitro purging (IFN-γ, CD34-positive stem cell selection, negative selection of Ph-positive cells), or in vivo purging (intensive chemotherapy), encourage further investigations of purged autologous BMT programs as an intensification procedure to (1) to increase the rate of durable cytogenetic responses and (2) to prolong survival.

The potential use of oncogene-targeted approaches (antisense oligonucleotides, conjugated toxins) for in vitro purging or in vivo therapy in autologous BMT are of interest. Combinations of these approaches may result in selective relatively nontoxic anti-CML therapies.

**Other Investigational Modalities**

New agents such as homoharringtonine have shown promising anti-CML efficacy.²⁸,²⁹ Homoharringtonine, used in a low-dose prolonged-infusion schedule in patients with late chronic-phase CML, resulted in CHR in 68% of patients, and in cytogenetic responses in 31% (17% major).³⁹ Its activity in combination with IFN-α in early chronic-phase CML is under investigation.³⁷ Other approaches of interest include differentiating agents (retinoids), agents that block cytokines that may mediate CML progression ( interleukin-1 [IL-1] receptor antagonists; IL-1 soluble receptors),³⁸ and new chemotherapeutic drugs.

**QUESTIONS OF INTEREST IN THE MANAGEMENT OF CML**

**Ph Chromosome-Negative CML**

About 10% of patients with a morphologic picture of CML do not have the Ph chromosome by cytogenetic analysis. One third of them will have BCR rearrangement by Southern blot molecular analysis (Ph-negative BCR-positive CML) and have a similar clinical picture, response to therapy, and outcome as Ph-positive CML.⁴¹ The remaining patients have a spectrum of disorders including myelodysplastic syndrome with a myeloproliferative component, chronic myelomonocytic leukemia, and true “Ph-negative, BCR-negative CML.” The latter, unlike Ph-positive CML, may have a low propensity for blastic transformation (25% to 50%), and an intermediate prognosis between chronic myelomonocytic leukemia (CMML) and Ph-positive CML.

**Thrombocytosis in CML**

Thrombocytosis in CML is a poor prognostic feature, and may be associated with thromboembolic or bleeding complications. In most patients, thrombocytosis responds to the regimen used in controlling CML. IFN-α is effective in controlling thrombocytosis in more than three quarters of patients.³² Anagrelide, an agent that prevents megakaryocytic maturation, also reduces the platelet counts, but has no effect on marrow megakaryocytosis.³³ In patients refractory or intolerant to the above treatments, thioptera is effective at doses of 75 mg/m² intravenously every 2 to 3 weeks until response occurs.

**CML and Pregnancy**

Pregnant women with CML may be managed with repeated leukophereses during the first one or two trimesters of pregnancy.³⁴ Leukopheresis may be performed when the WBC count exceeds 70 to 100 × 10⁹/µL, or in symptomatic conditions. Hydroxyurea has been used in the later stages of pregnancy without untoward or teratogenic effects on the fetus. IFN-α is teratogenic in animal models. Two of our patients became pregnant while undergoing IFN-α therapy; the treatment was discontinued, and both delivered normal babies. However, patients on IFN-α therapy should have adequate contraception, because the treatment has the potential of inducing serious complications in the newborn (underweight babies, malformations).

**Role of Splenectomy in CML**

The spleen may be an initial site of CML transformation in a minority of patients (? less than 10%).³⁵ These may be the patients with persistent significant splenomegaly despite adequate disease control in the BM and blood. Studies randomizing patients to splenectomy or no splenectomy in early chronic phase,³⁶ or before allogeneic BMT have not shown a survival advantage.³⁷,³⁸ Splenectomy before allogeneic BMT may result in earlier hematopoietic recovery, but is associated with a higher incidence of GVHD in patients without palpable splenomegaly. Based on current knowledge, splenectomy in chronic-phase CML may be considered for persistent significant splenomegaly on optimal therapy, particularly with evidence of hypersplenism, or with suboptimal treatment delivery because of anemia or thrombocytopenia. Splenectomy in CML transformation may be associated with increased morbidity and mortality without an obvious therapeutic benefit.

**When Should Molecular Studies Be Performed in CML?**

In patients with a morphologic picture of CML but no Ph-positive metaphases, Southern blot analysis for BCR rearrangement will identify the subset of Ph-negative, BCR-positive CML patients. This will help direct their therapy (as for Ph-positive CML) and prognosticating on the course of the disease.
The value of molecular studies to detect 3' versus 5' breakpoints, or b3a2 versus b2a2 messages, is controversial. It should be pursued in investigational studies, but not as routine tests in clinical practice.

In the follow-up of patients on treatment, BCR rearrangement quantification has not yet been standardized in relation to cytogenetic studies. Once the equivalence of the two studies for measuring the degree of Ph-suppression is established, serial follow-ups with BCR quantification may be easier, faster, and less expensive. The test is currently useful to monitor the effect of therapy in patients with Ph-negative BCR-positive disease. Southern blot analysis is equivalent, but not superior, to cytogenetic studies in assessing minimal residual disease (ie, Ph-positive 0%).

Polymerase chain reaction (PCR) studies to detect residual disease at $10^{-4}$ to $10^{-3}$ level is an important investigational tool in Ph-positive CML. In our experience, PCR studies for BCR-ABL were positive in all 40 patients who had 0% Ph-positive metaphases by cytogenetic studies after IFN-α therapy.8 Other groups have reported some cases with PCR-negativity.9-12 Detection of residual disease at this level may not be clinically relevant because it has not predicted consistently for subsequent relapse. Among patients studied after allogeneic BMT, more than 75% will have at least one PCR-positive test within 12 months post BMT, and 40% to 50% will be positive at 12 months.9-12 Only 25% of the latter group will have CML relapse. Consequently, PCR studies for BCR-ABL should be pursued in investigational studies of therapeutic interventions in CML, but not in current community practice.

FUTURE DIRECTIONS

Future investigations should aim at improving and maximizing the intensity and duration of cytogenetic responses in CML, ie, suppressing the Ph-positive clones responsible for disease propagation and progression. This could be achieved through (1) optimizing IFN-α combination regimens (with low-dose ara-C, homoharringtonine, or other agents); (2) investigating new approaches in allogeneic BMT that improve the efficacy and safety of the procedure; (3) pursuing the leads in purged autologous BMT as an intensification procedure, followed by IFN-α or other maintenance therapies; (4) developing selective antioncogene targeted therapies; and (5) discovering new agents with specific anti-CML efficacy. The sum of such programs will hopefully improve significantly the prognosis in CML over the next decade.

REFERENCES

23. Mills KI, Birnie GD: Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 78:1155, 1991
25. Clark SC, McLaughlin J, Crist WM: Unique forms of the abl
tyrosine kinase distinguish Ph1-positive acute lymphocytic leukae-
26. Secker-Walker LM, Cooke HMG, Browett PJ, Shippey CA, 
Norton JD, Coustan-Smith E, Hoffbrand AV: Variable Philadelphia
breakpoints and potential lineage restriction of bcr rearrange-
interactions with marrow stroma of haematopoietic progenitor cells
cells are deficient in cell surface LFA-3; modulation by alpha-inter-
feron in vitro and in vivo. Blood 72:231a, 1988 (abstr 836, suppl 1)
29. Schlossman F, Chess L, Humphreys RE, Strominger JL: Dis-
btribution of la-like molecules on the surface of normal and leuk-
emic human cells. Proc Natl Acad Sci USA 73:1288, 1976
30. Strife A, Clarkson B: Biology of chronic myelogenous leuke-
tion at the primary defect? Semin Hematol 25:1, 1988
32. Fialkow PJ, Martin PJ, Najfeld V, et al: Evidence for a multi-
step pathogenesis of chronic granulocytic leukemia. Blood 58:158,
1981
33. Gupta CM, Dalousek DK, Eaves CJ, Eaves AC: Cyto genetic
studies of early myeloid progenitor compartments in Ph positive
chronic myeloid leukemia. I. Persistence of Ph1 negative commit-
ted progenitors that are suppressed from differentiating in vivo. Br J
Haematol 56:633, 1984
hemopoietic progenitors in a G6PD heterozygote with chronic
myelogenous leukemia revealed after long-term marrow cultures. Am
35. Goto T, Nishikori M, Arliin Z: Growth characteristics of leu-
kenia and normal hematopoietic cells in Ph1 + chronic myeloge-
nous leukemia and effects of intensive treatment. Blood 59:793,
1982
36. Goldman JM, Grosveld G, Baltimore D, Gale RP: Chronic
myelogenous leukemia—The unfolding saga. Leukemia 4:163,
1990
37. McLaughlin J, Chianese E, Witte O: In vitro transformation of
immature hematopoietic cells by the P210 bcr/abl oncogene
product of the Philadelphia chromosome. Proc Natl Acad Sci USA
84:6558, 1987
38. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic
myelogenous leukemia by the P210 bcr/abl gene of the
oncogene induces lymphomas in transgenic mice. Mol Cell Biol
9:2798, 1989
40. Talpaz M, Kantarjian HM, McCredie KB, et al: Clinical in vesti-
gation of human alpha interferon in chronic myelogenous leuke-
remission and cytogenetic improvement induced by recombinant
human interferon alpha A in chronic myelogenous leukemia. N
as therapy for Ph1-positive chronic myelogenous leukemia. A study
of 82 patients treated with intermittent or daily administration.
Blood 72:642, 1988
in the treatment of chronic myelogenous leukemia. Semin Oncol
16:29, 1987
44. Ozer H, George S, Pettenati M, et al: Subcutaneous alpha-inter-
feron in untreated chronic phase Philadelphia chromosome posi-
tive chronic myelogenous leukemia—No evidence for significant
improvement in response duration or survival. Blood 89:358a,
1992 (abstr, suppl 1)
human interferon (IFN) alpha-2b in chronic myelogenous leuke-
mia—Dose dependency of response and frequency of neutralizing
46. Montastruc M, Reiffers J, Bilhou-Nabera C, et al: Recombi-
nant interferon alpha as initial treatment for chronic myelogenous
leukemia. Chronic Myeloid Leukemia 2nd International Confer-
ence. Bologna, Italy, 1992, p 103
treated by interferon alpha-2b vs hydroxyurea alone—Preliminary
report of a large multicenter randomized trial. Blood 80:358a, 1992
(abstr, suppl 1)
48. Baccarani M, for the Italian Cooperative Study Group on
Chronic Myeloid Leukemia: Prognostic study of alpha-interferon
(IFN)-treated chronic myelogenous leukemia (CML) patients: II
Predicting survival. Chronic Myeloid Leukemia, 2nd International
Conference. Bologna, Italy, 1992, p 101
49. Ronnblom LE, Alm FV, Oberg KE: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann In-
50. Conlon KC, Uriba WJ, Smith JW, Steis RG, Longo DL,
Clark JW: Exacerbation of symptoms of autoimmune disease in
51. Zuffa E, for the Italian Cooperative Study Group on Chronic
Myeloid Leukemia: The Italian prospective study of interferon-alpha
(Roferon-A) vs. chemotherapy—Karyotypic response and sur-
vival at 4 years. Chronic Myeloid Leukemia, 2nd International Con-
ference. Bologna, Italy, 1992, p 163
52. Lazzarino M, Morra E, Merante S, Corso A, Orlandi E, Asto-
ri C, Buonanno C, Bonfichi M, Santagostino A, Bernasconi C:
Evaluation of response to different therapies in chronic myeloge-
nous leukemia according to risk assessment at diagnosis. Chronic
Myeloid Leukemia, 2nd International Conference. Bologna, Italy,
1992, p 205
myelogenous leukemia with recombinant interferon-
gamma. Blood 70:947, 1987
therapy with interferon alpha-2B plus low-dose interferon gamma
in pretreated patients with Ph-positive chronic myelogenous leuke-
L, Gutterman JU: A phase II study alternating alpha-2a-in-
feron and gamma-interferon therapy in patients with chronic
J, Marcus S: Phase II study of recombinant beta interferon in chronic
myelogenous leukemia. Blood 72:797a, 1988 (abstr, suppl 1)
EH, McCredie KB, Gutterman J, Freireich EJ: Intensive chemo-
therapy induction followed by alpha interferon maintenance in pa-
ients with Philadelphia chromosome-positive chronic myeloge-
58. Sokal J, Bigner S, Tantravahi R, Robertson MJ, Griffin J, Can-
elos GP: Low-dose cytotoxic ara-binose induces cytogenetic remis-
From www.bloodjournal.org by guest on September 24, 2017. For personal use only.
sions in patients with stable phase chronic myeloid leukemia. Blood 76:259a, 1990 (abstr, suppl 1)


67. Advisory Committee of the International Bone Marrow Transplant Registry: Report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 4:221, 1989


70. Gratwohl A: Bone marrow transplantation for chronic myelogenous leukemia. The European Bone Marrow Transplantation Experience in Chronic Myelogenous Leukemia. 2nd International Conference. Bologna, Italy, 1992


72. Hughes T, Brito-Babapulle F, Marcus RE: Transient Ph negativity after autografting with blood-derived stem cells for patients with chronic myeloid leukemia in chronic phase. Bone Marrow Transplant 4:51, 1989 (suppl 1)


86. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. Cancer 54:333, 1984


94. Hughes T, Gareth JM, Martiat P, Goldman JM: Detection


Chronic myelogenous leukemia: a concise update

HM Kantarjian, A Deisseroth, R Kurzrock, Z Estrov and M Talpaz